Navigation Links
Healthcare Technologies Announces New Date for the Shareholders Meeting to Approve the Nexgen Biofuels Transaction
Date:10/19/2007

PETACH TIKVA, Israel, October 19 /PRNewswire-FirstCall/ -- Healthcare Technologies Ltd. (NASDAQ: HCTL), announced today that the extraordinary general meeting of its shareholders, previously scheduled for September 30, 2007, will be held on December 4, 2007 at 4:00 p.m., at the offices of Yigal Arnon & Co., 1 Azrieli Center, Round Tower, 47th Floor, Tel Aviv, Israel.

At the meeting, shareholders will be asked to approve the previously announced Asset Purchase Agreement with NexGen Biofuels, Inc, Mac Bioventures Inc. and Gamida for Life B.V. and the transactions contemplated thereby, as a result of which the Company's business will be in the field of renewable fuels rather than biotechnology and medical devices.

Shareholders of record of the Company as of the close of business in New York on October 25, 2007, are entitled to vote at the Meeting.

The Notice, the previously distributed Proxy Statement and a Supplement to the Proxy Statement associated with the Meeting are available on the SEC's website at http://www.sec.gov and on the Company's website at http://www.hctech.com. Materials for the meeting will be sent to all shareholders of record. Proxy cards that were returned for the September 30th meeting are no longer valid with respect to the December 4, 2007 Meeting, and shareholders must vote again for their vote to count at the December 4, 2007 Meeting. Brokers cannot vote shareholders' shares in connection with the Meeting without instructions from the shareholders.

Shareholders who need additional copies of the proxy materials or have questions regarding the Meeting, including the procedures for voting shares, should call The Altman Group, the Company's proxy solicitor, toll-free at +1-800-622-1588 (from the United States) or +1-201-806-7300 (from other locations).

Closing of the transactions contemplated by the Agreement is subject to the completion of due diligence by the parties, the receipt of the necessary corporate, regulatory and third party approvals, including Healthcare's shareholders and the approval of the Israeli District Court and other closing conditions. No assurance can be given that the transactions contemplated by the Agreement will close.

About Healthcare Technologies

Healthcare Technologies Ltd. through it subsidiaries and affiliates Gamidor Diagnostics (1984) Ltd., Danyel Biotech Ltd. and Savyon Diagnostics Ltd., specializes in the development, manufacturing and marketing of clinical diagnostic test kits and provides services and tools to diagnostic and biotech research professionals in laboratory and point of care sites worldwide.

About NexGen Biofuels, Inc.

NexGen is operating in the business of alternative fuels. NexGen plans to build and operate four ethanol and one biodiesel plant with production primarily within in the United States. NexGen is currently in the process of acquiring and developing its proposed plants and has not conducted any significant business operations or generated any operating revenues to date. It is NexGen's intention to produce 100 million gallons of annual ethanol production per ethanol site, and 100 million gallons of annual biodiesel production.

SAFE HARBOR: This press release contains certain forward looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward looking statement made by or on behalf of Healthcare Technologies Ltd. Many factors could cause the actual results, performance or achievements of Healthcare or the above described transaction to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, among others: satisfaction of the closing conditions to the agreement; the agreement becoming subject to termination if the Closing has not taken place on or before December 31, 2007, receipt of shareholder, regulatory and third party approvals, including the approval of the District Court of Tel Aviv; the satisfaction and completion of due diligence by the parties to the agreement; the receipt by Healthcare of a satisfactory valuation of NexGen's assets; a non-binding offer to purchase Healthcare's subsidiaries previously sent to us by Inverness Medical Innovations Inc., to which, as any negotiations with Inverness would be a breach of the NexGen Agreement, Healthcare has refrained from any discussions with Inverness. Readers are referred to the documents filed by the company with the Securities and Exchange Commission, specifically the Proxy Statement filed on August 16, 2007 and Supplement to the Proxy Statement filed on or about the date hereof concerning the meeting and most recent report on Form 20F that identifies important risks which could cause actual results to differ from those contained in the forward looking statements.

Contact:

Eran Rotem

CFO

+972-3-9277232/3


'/>"/>
SOURCE Healthcare Technologies Ltd
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Healthcare sector is now a multi billion-dollar industry in India
2. Iodex goes to SmithKline Beecham consumer Healthcare
3. Healthcare Professionals Might Want To Rethink Their Dress Code
4. WHO report asks for improved healthcare for mother and child
5. New X-ray machine launched by GE Healthcare
6. India To March Ahead in The Global HealthCare Competition
7. Medical Fraternity Urged To Revamp Indian Healthcare
8. British Healthcare Mission Explores Partnership Possibilities With Indian Healthcare Sector
9. Need For Social Churning Emphasized In CMC Meet On ‘Leadership In Healthcare
10. LINK Applied Genomics Programme Promises To Revolutionize Healthcare Systems
11. India Can Manage World’s Healthcare Crisis By 202
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... ... ... More than 80 representatives of the Hepatitis B Foundation , Hepatitis ... an event on National Hepatitis Testing Day outside of Philadelphia City Hall to raise ... of liver cancer. , Foundation leaders and the citywide coalition they created, Hep B ...
(Date:5/31/2016)... ... May 31, 2016 , ... ... Houston Healthconnect’s (Healthconnect) regional health information exchange, which enables physicians at SJMC’s two ... their patients from other participating organizations in the exchange. SJMC’s membership in the ...
(Date:5/31/2016)... ... May 31, 2016 , ... ... Corporation, he knew it was something that contractors should have at their disposal ... it gets,” says Butch, CertainTeed’s Director of Contractor Programs. , As a ...
(Date:5/31/2016)... ... May 31, 2016 , ... Spartan Bioscience today introduced the ... and convenience. , The Cube is exceptionally small—it takes up the space of ... easily into any space, whether in a hospital, doctor’s office, or pharmacy. , ...
(Date:5/31/2016)... ... May 31, 2016 , ... Like jewels in a crown, the multiple awards ... is home to Ontario’s leading day spa and one of Canada’s few accredited 5 ... a unique concept to combine spa services with hair and beauty services ...
Breaking Medicine News(10 mins):
(Date:5/31/2016)... JACKSON, Mich. , May 31, 2016 /PRNewswire/ ... a market-leading provider of anesthesia information management systems ... Doug Marcey as Vice President of ... establish and lead all aspects of the company,s ... and Plexus TG customers to determine the expansion ...
(Date:5/31/2016)... May 31, 2016 Aloe vera ... food, cosmetics and pharmaceuticals, with global volume to surpass ... 1.6 Bn. Demand for aloe vera extracts ... yogurts will continue its upward momentum in 2016 as ... boost positive sentiment on aloe vera, with wide-ranging applications ...
(Date:5/31/2016)... NESS ZIONA, Israel , ... a regenerative medicine company utilizing its proprietary plant-based rhCollagen ... has received authorization from the Chief Scientist of ... approximately 50% of its NIS 12 million development project ... million, measurably higher than last year,s authorized grant, which ...
Breaking Medicine Technology: